The IPO market is expected to be quite active this week, with a number of new launches anticipated across various exchanges. Investors are keenly watching several companies making their debut, with Anthem Biosciences standing out as a prominent listing to watch.

Anthem Biosciences IPO Details

Anthem Biosciences is launching a main-board IPO consisting of 59,575,319 equity shares with a face value of ₹2 each, aggregating up to ₹3,395.79 crores. The issue is priced at ₹570 per share, with a minimum order quantity of 26 shares. The IPO is open for subscription from July 14, 2025, and closes on July 16, 2025. Allotment is expected to be finalized on July 17, 2025, and the shares are proposed to be listed on both the BSE and NSE on July 21, 2025.

The IPO is entirely an offer for sale of 5.96 crore shares. The price band is set between ₹540 and ₹570 per share. Retail investors can apply for a minimum lot size of 26 shares, requiring an investment of ₹14,040. A reservation of up to 158,653 shares is available for employees at a discount of ₹50 per share.

JM Financial Limited is the book-running lead manager, and Kfin Technologies Limited is the registrar for the issue.

About Anthem Biosciences

Established in 2006, Anthem Biosciences is a contract research, development, and manufacturing organization (CRDMO) that offers integrated services in drug discovery, development, and manufacturing. The company specializes in fermentation-based APIs, including probiotics, enzymes, peptides, and biosimilars, catering to both biotech startups and large pharma companies worldwide. As of now, Anthem has 196 active projects, including 170 discovery projects, with R&D spanning RNAi, ADCs, and peptides.

The company holds ISO certifications for its quality, environmental, and occupational health and safety management systems. Anthem Biosciences has demonstrated consistent revenue growth, increasing from ₹1,056.92 crores in FY23 to ₹1,844.55 crores in FY25. The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crore in 2024, and a profit of ₹451.26 crores in 2025 against ₹367.31 crores in 2024.

Other IPOs to Watch

While Anthem Biosciences is a key highlight, several other IPOs are also slated for this week. These include:

• NIQ Global Intelligence plc: Expected to launch on July 23, 2025, on the NYSE, with an offer amount of $1.38 billion.
• Carlsmed, Inc.: This IPO is scheduled for July 23, 2025, on the NASDAQ Global Select, aiming to raise $123.28 million.
• Cre8 Enterprise Ltd: Listing on NASDAQ Capital, this IPO is also expected on July 23, 2025.
• Accelerant Holdings: Anticipated to launch on July 24, 2025, on the NYSE, with a target raise of $665.79 million.
• McGraw Hill, Inc.: Also expected on July 24, 2025, on the NYSE, seeking to raise $617.07 million.

Market Sentiment

The IPO market is dynamic, and while dates are usually set close to launch, they remain subject to change. Investors are advised to conduct thorough research and consider various factors before investing in IPOs.